ITMCTR1900002496招募中4 期
Efficacy of liraglutide combined with insulin pump in type 2 diabetes
XuZhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 性别
- All
入选标准
- •(1) To meet the diagnostic criteria for type 2 diabetes mellitus with poor blood sugar control;
- •(2) aged 18 to 70, men and women are not limited;
- •(3) HbA1c is greater than or equal to 9%;
- •(4) patients and their families agree and sign agreements.
排除标准
- •(1) diabetes mellitus with pregnancy;
- •(2) patients with cerebral infarction or severe mental illness, unconsciousness;
- •(3) patients with infectious diseases such as active pulmonary tuberculosis;
- •(4) patients with severe cardiopulmonary and liver and kidney dysfunction;
- •(5) insulin allergists;
- •(6) those who do not cooperate with drugs.
研究者
相似试验
已完成
不适用
Effects of liraglutide add-on to insulin therapy in patients with type 2 diabetesJPRN-UMIN000030622Yokohama City University80
进行中（未招募）
1 期
Efficacy and safety of liraglutide in combination with metformin compared to metformin alone, in children and adolescents with type 2 diabetes.MedDRA version: 18.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Diabetes Mellitus, Type 2EUCTR2011-002605-29-ATovo Nordisk A/S150
进行中（未招募）
1 期
Efficacy and safety of liraglutide in combination with metformin compared to metformin alone, in children and adolescents with type 2 diabetes.Diabetes Mellitus, Type 2EUCTR2011-002605-29-PTovo Nordisk A/S135
进行中（未招募）
1 期
Efficacy and safety of liraglutide in combination with metformin compared to metformin alone, in children and adolescents with type 2 diabetes.Diabetes Mellitus, Type 2MedDRA version: 19.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2011-002605-29-DKovo Nordisk A/S150
进行中（未招募）
1 期
Efficacy and safety of liraglutide in combination with metformin compared to metformin alone, in children and adolescents with type 2 diabetes.A 26-week double-blind, randomised, parallel group, placebo controlled multi-centre trial followed by a 26-week open-label extension.Diabetes Mellitus, Type 2EUCTR2011-002605-29-PLovo Nordisk A/S135